tetano
Editor, Senior Moderator
Cell Rep
. 2021 Feb 23;108837.
doi: 10.1016/j.celrep.2021.108837. Online ahead of print.
Use of convalescent serum reduces severity of COVID-19 in nonhuman primates
Robert W Cross[SUP] 1 [/SUP], Abhishek N Prasad[SUP] 1 [/SUP], Viktoriya Borisevich[SUP] 1 [/SUP], Courtney Woolsey[SUP] 1 [/SUP], Krystle N Agans[SUP] 1 [/SUP], Daniel J Deer[SUP] 1 [/SUP], Natalie S Dobias[SUP] 1 [/SUP], Joan B Geisbert[SUP] 1 [/SUP], Karla A Fenton[SUP] 1 [/SUP], Thomas W Geisbert[SUP] 2 [/SUP]
Affiliations
Abstract
Passive transfer of convalescent plasma or serum is a time-honored strategy for treating infectious diseases. Human convalescent plasma containing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently being used to treat patients with coronavirus disease 2019 where clinical efficacy trials are ongoing. Here, we assess therapeutic passive transfer in groups of SARS-CoV-2-infected African green monkeys with convalescent sera containing either high or low anti-SARS-CoV-2 neutralizing antibody titers. Differences in viral load and pathology are minimal between monkeys that receive the lower titer convalescent sera and untreated controls. However, lower levels of SARS-CoV-2 in respiratory compartments, reduced severity of virus-associated lung pathology, and reductions in coagulopathy and inflammatory processes are observed in monkeys that receive high titer sera versus untreated controls. Our data indicate that convalescent plasma therapy in humans may be an effective strategy provided that donor sera contain high anti-SARS-CoV-2 neutralizing titers given in early stages of the disease.
Keywords: COVID-19; SARS-CoV-2; antibodies; convalescent serum; coronavirus; nonhuman primate; viral pneumonia.
. 2021 Feb 23;108837.
doi: 10.1016/j.celrep.2021.108837. Online ahead of print.
Use of convalescent serum reduces severity of COVID-19 in nonhuman primates
Robert W Cross[SUP] 1 [/SUP], Abhishek N Prasad[SUP] 1 [/SUP], Viktoriya Borisevich[SUP] 1 [/SUP], Courtney Woolsey[SUP] 1 [/SUP], Krystle N Agans[SUP] 1 [/SUP], Daniel J Deer[SUP] 1 [/SUP], Natalie S Dobias[SUP] 1 [/SUP], Joan B Geisbert[SUP] 1 [/SUP], Karla A Fenton[SUP] 1 [/SUP], Thomas W Geisbert[SUP] 2 [/SUP]
Affiliations
- PMID: 33662255
- DOI: 10.1016/j.celrep.2021.108837
Abstract
Passive transfer of convalescent plasma or serum is a time-honored strategy for treating infectious diseases. Human convalescent plasma containing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently being used to treat patients with coronavirus disease 2019 where clinical efficacy trials are ongoing. Here, we assess therapeutic passive transfer in groups of SARS-CoV-2-infected African green monkeys with convalescent sera containing either high or low anti-SARS-CoV-2 neutralizing antibody titers. Differences in viral load and pathology are minimal between monkeys that receive the lower titer convalescent sera and untreated controls. However, lower levels of SARS-CoV-2 in respiratory compartments, reduced severity of virus-associated lung pathology, and reductions in coagulopathy and inflammatory processes are observed in monkeys that receive high titer sera versus untreated controls. Our data indicate that convalescent plasma therapy in humans may be an effective strategy provided that donor sera contain high anti-SARS-CoV-2 neutralizing titers given in early stages of the disease.
Keywords: COVID-19; SARS-CoV-2; antibodies; convalescent serum; coronavirus; nonhuman primate; viral pneumonia.